VP of R&D secures 3-year employment agreement with $1.3M change-in-control severance
BRTX has more than doubled off its 52-week low of $0.159 on light trading volume (0.1× avg).
Summary
BioRestorative Therapies signed a new 3-year employment agreement for its VP of R&D, including a $575,000 salary and a potential $1.3 million severance package that triggers on a change in control, despite the company's severe financial challenges.
Key Events · Executive and Board Changes · BRTX
-
New Employment Agreement for VP R&D
Francisco Silva, Vice President of Research and Development, entered into a new three-year employment agreement effective June 10, 2026.
-
Executive Compensation Details
The agreement maintains an annual salary of $575,000 and includes eligibility for an annual cash bonus of up to 50% of salary.
-
Substantial Severance Package
The agreement provides for a severance payment of 1.5 times the sum of salary and maximum bonus, totaling approximately $1.3 million, upon termination without cause or resignation for good reason.
-
Change-in-Control Trigger
The severance package and full vesting of equity awards are triggered upon a change in control, regardless of whether employment terminates.
Analysis · BRTX · Industrial Applications And Services
BioRestorative Therapies, a company facing a 'going concern' warning, Nasdaq delisting risk, and recent dilutive actions, has entered into a new three-year employment agreement with its Vice President of Research and Development, Francisco Silva. The agreement maintains his $575,000 annual salary and includes a substantial severance package of approximately $1.3 million (1.5 times salary plus maximum bonus) that triggers upon termination without cause or a change in control, even if employment does not cease. This commitment represents a significant potential liability for a company with an $8.98 million market capitalization, raising concerns about executive compensation and corporate governance amidst ongoing financial distress and a pattern of generous executive bonuses.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRTX was trading at $0.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.16 to $2.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.